Background Several trials evaluating the effect of prostate-specific antigen (PSA) testing on
prostate-cancer mortality have shown conflicting results. We updated prostate-cancer …

Background The European Randomized Study of Screening for Prostate Cancer was
initiated in the early 1990s to evaluate the effect of screening with prostate-specific–antigen …

Importance The Cluster Randomized Trial of PSA Testing for Prostate Cancer (CAP)
reported no effect of prostate-specific antigen (PSA) screening on prostate cancer mortality …

Abstract Background The European Randomized study of Screening for Prostate Cancer
(ERSPC) has previously demonstrated that prostate-specific antigen (PSA) screening …

Importance Prostate cancer screening with the prostate-specific antigen (PSA) test remains
controversial. Objective To review evidence from randomized trials and related modeling …

Background Despite more than a decade of prostate-specific antigen (PSA)-based
screening, the proven impact of screening on mortality due to prostate cancer continues to …

Background The effect of screening with prostate-specific–antigen (PSA) testing and digital
rectal examination on the rate of death from prostate cancer is unknown. This is the first …

Background Prostate cancer (PC) screening with prostate-specific antigen (PSA) has been
shown to decrease PC mortality by the European Randomized Study of Screening for …

Background Evidence from randomized trials on the effects of screening for prostate cancer
(PCa) on disease-specific mortality accumulates slowly with increasing follow-up. Objective …

Importance Prostate cancer screening remains controversial because potential mortality or
quality-of-life benefits may be outweighed by harms from overdetection and overtreatment …